You are here

Schizophr Res DOI:10.1016/j.schres.2004.09.005

Program to improve cognitive functioning in patients with schizophrenia: reflections.

Publication TypeJournal Article
Year of Publication2004
AuthorsScolnick, E
JournalSchizophr Res
Volume72
Issue1
Pages75-7
Date Published2004 Dec 15
ISSN0920-9964
KeywordsAntipsychotic Agents, Clinical Trials as Topic, Cognition Disorders, Consensus, Humans, Program Development, Schizophrenia
Abstract

Cognitive dysfunction in patients who suffer from schizophrenia is a major clinical problem. For such patients, the neurobiological cause(s) for the cognition deficits are not clear. Treatments with high doses of compounds that work at the coagonist site of the NMDA receptor have demonstrated that some degree of improvement can be elicited in patients. Thus, the NIMH effort to delineate the clinical responses that would allow new drugs to be registered for this use is very timely. Significant credit is due Dr. Steven Hyman and his colleagues for stimulating this bold initiative. Many problems remain to be solved to accomplish the goal. This article articulates a few such problems.

URLhttp://linkinghub.elsevier.com/retrieve/pii/S0920-9964(04)00340-8
DOI10.1016/j.schres.2004.09.005
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/15531409?dopt=Abstract

Alternate JournalSchizophr. Res.
PubMed ID15531409